These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1885418)

  • 1. Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group.
    García-Rodriguez JA; García Sánchez JE; Trujillano I; Sánchez de San Lorenzo A
    J Antimicrob Chemother; 1991 May; 27(5):599-606. PubMed ID: 1885418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Can meropenem E-test be used to estimate the presence of carbapenem resistance gene cfiA among Bacteroides fragilis strains?].
    Toprak Ülger N; Ilki A; Ozel N; Balkan N; Söyletir G
    Mikrobiyol Bul; 2011 Jul; 45(3):385-91. PubMed ID: 21935771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
    Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis.
    White RL; Friedrich LV; Manduru M; Mihm LB; Bosso JA
    Diagn Microbiol Infect Dis; 2001 Jan; 39(1):39-47. PubMed ID: 11173190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates.
    Iaconis JP; Nadler HL; Sheikh W
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S361-3. PubMed ID: 7548598
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1990; 13(1):57-61. PubMed ID: 2331851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
    Yim J; Lee Y; Kim M; Seo YH; Kim WH; Yong D; Jeong SH; Lee K; Chong Y
    Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
    Falagas ME; McDermott L; Snydman DR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria].
    Bland S; Sedallian A; Grollier G; Mory F; Houcke I; Dubreuil L
    Pathol Biol (Paris); 1995 Apr; 43(4):289-93. PubMed ID: 7567117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selection of resistance mutants and bacteriostatic and bactericidal activity of meropenem and imipenem against Acinetobacter spp].
    Villar HE; Laurino G; Arena MF; Hoffman M
    Enferm Infecc Microbiol Clin; 1997 Mar; 15(3):140-3. PubMed ID: 9235053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of meropenem against Pseudomonas aeruginosa.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F; Glupczynski Y
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():169-74. PubMed ID: 2509414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The postantibiotic effect of meropenem and imipenem on selected bacteria.
    Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of antimicrobial activity of amoxicillin/clavulanic acid and metronidazole against beta-lactamase-producing Bacteroides fragilis group.
    García-Rodríguez JA; García Sánchez JE; Trujillano I; Muñoz-Bellido JL
    J Chemother; 1990 Feb; 2(1):11-6. PubMed ID: 2332779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.
    White R; Friedrich L; Burgess D; Warkentin D; Bosso J
    Antimicrob Agents Chemother; 1996 Apr; 40(4):904-8. PubMed ID: 8849249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
    Hoellman DB; Kelly LM; Credito K; Anthony L; Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2002 Jan; 46(1):220-4. PubMed ID: 11751138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro killing activity of meropenem versus imipenem against multiresistant nosocomial Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Chemother; 1995 Jun; 7(3):179-83. PubMed ID: 7562010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.